Pharmaceutical manufacturers spent $1.9 billion on direct-to-consumer advertising of prescription drugs between January and September 2000, the same amount spent in all of 1999, according to Newtown, PA-based Scott-Levin's "Direct-to-Consumer Advertising Audit." The audit, which surveyed over 4,000 consumers and 3,000 physicians, found that two major therapeutic classes - antihistamines and COX-2 inhibitors - generated 20% ($390 million) of advertising expenditures in the first nine months of 2000.
Pharmaceutical manufacturers spent $1.9 billion on direct-to-consumer advertising of prescription drugs between January and September 2000, the same amount spent in all of 1999, according to Newtown, PA-based Scott-Levin's "Direct-to-Consumer Advertising Audit." The audit, which surveyed over 4,000 consumers and 3,000 physicians, found that two major therapeutic classes - antihistamines and COX-2 inhibitors - generated 20% ($390 million) of advertising expenditures in the first nine months of 2000.
Spending on antihistamines continues to outpace other therapeutic classes, according to Scott-Levin. The $197.2 million spent by manufacturers to advertise their allergy products to consumers accounted for 10.2% of all industry spending on DTC advertising between January and September 2000.
In terms of print ad recall, a key measure of ad effectiveness, consumers seem to remember drugs moderately well. The audit found that:
•Â Within the antihistamine market, consumers in the third quarter of 2000 were just as likely to remember seeing a print ad for Kenilworth, NJ-based Schering-Plough Corp.'s Claritin-D® (loratadine/pseudoephedrine sulfate, USP) (17%) as they were to remember seeing an ad for Parsippany, NJ-based Aventis Pharma AG's Allegra® (fexofenadine HCl) (17%).
•Â Of the consumers who remembered seeing the Claritin-D ad, only 3% could correctly identify the name of the product as Claritin-D, but 34% identified it as "classic" Claritin. Consumers who recalled seeing the Allegra ad were able to correctly identify it 22% of the time. Ads for New York-based Pfizer Inc.'s Zyrtec® (cetirizine HCl) were remembered by 11% of consumers, with 20% of those recalling the ad correctly identifying the brand.
• In the third quarter of 2000, 12% of physicians noticed an increase in patient-initiated discussions about Allegra, and 75% of those doctors indicated that requests for the product had grown. Fourteen percent of doctors reported an increase in discussions about Claritin, and 76% of those physicians also noticed an increase in requests. Five percent of physicians noticed an increase in Zyrtec discussions, and 79% of those doctors also reported an increase in requests.
COX-2 inhibitors finished second in spending on consumer advertising in the first nine months of 2000. Some highlights:
•Â Expenditures on consumer ads for Whitehouse Station, NJ-based Merck & Co. Inc.'s Vioxx® (rofecoxib tablets) and Peapack, NJ-based Pharmacia Corp. and Pfizer's Celebrex⢠(celecoxib) totaled $192.9 million (9.9% of the industry total).
•Â The Celebrex print advertisement was seen by 30% of consumers and correctly identified by 13% of those consumers. The Vioxx ad was seen by 21% of consumers and correctly identified by 19%.
•Â About 22% of surveyed physicians noted an increase in patient-initiated discussions about Celebrex, and 78% of those doctors heard more requests for the drug. About 18% said more patients started discussions about Vioxx, and 83% of those doctors received more requests for the brand.
Attitudes toward direct-to-consumer ads varied among physicians and consumers, according to the audit. In the third quarter of 2000, 39% of consumers were positive about DTC ads, 22% were negative and 39% were neutral.
In contrast, 45% of physicians were negative about DTC ads, 28% were positive and 26% were neutral. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.